Pfizer Inc. (NYSE:PFE) Shares Acquired by Legacy Trust

Posted by Defense World Staff on Jul 3rd, 2023

Legacy Trust lifted its holdings in Pfizer Inc. (NYSE:PFE – Free Report) by 6.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,012 shares of the biopharmaceutical company’s stock after purchasing an additional 993 shares during the period. Legacy Trust’s holdings in Pfizer were worth $653,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of PFE. Front Street Capital Management Inc. raised its stake in Pfizer by 4.3% during the 1st quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares during the period. Cape Cod Five Cents Savings Bank raised its position in Pfizer by 0.7% during the third quarter. Cape Cod Five Cents Savings Bank now owns 32,775 shares of the biopharmaceutical company’s stock valued at $1,435,000 after buying an additional 225 shares during the period. Synergy Asset Management LLC lifted its stake in Pfizer by 3.3% in the 4th quarter. Synergy Asset Management LLC now owns 7,287 shares of the biopharmaceutical company’s stock worth $373,000 after acquiring an additional 236 shares in the last quarter. Motco boosted its position in Pfizer by 0.8% during the 4th quarter. Motco now owns 31,376 shares of the biopharmaceutical company’s stock worth $1,608,000 after acquiring an additional 236 shares during the period. Finally, Alterity Financial Group LLC grew its stake in Pfizer by 4.6% during the 4th quarter. Alterity Financial Group LLC now owns 5,474 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 243 shares in the last quarter. Institutional investors and hedge funds own 67.80% of the company’s stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the firm’s stock in a transaction that occurred on Monday, May 8th. The stock was purchased at an average price of $38.58 per share, for a total transaction of $38,580.00. Following the purchase, the director now directly owns 6,000 shares in the company, valued at $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is currently owned by corporate insiders.

Pfizer Stock Up 1.6 %

PFE opened at $36.68 on Monday. The firm has a market cap of $207.07 billion, a P/E ratio of 7.22, a price-to-earnings-growth ratio of 1.22 and a beta of 0.61. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37. The business has a 50 day moving average price of $38.32 and a 200 day moving average price of $42.05. Pfizer Inc. has a twelve month low of $35.76 and a twelve month high of $54.93.

Pfizer (NYSE:PFE – Free Report) last released its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.23. The company had revenue of $18.28 billion for the quarter, compared to analyst estimates of $16.49 billion. Pfizer had a net margin of 31.25% and a return on equity of 37.53%. The company’s quarterly revenue was down 28.8% compared to the same quarter last year. During the same quarter last year, the firm posted $1.62 earnings per share. Research analysts forecast that Pfizer Inc. will post 3.35 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be given a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 4.47%. The ex-dividend date is Thursday, July 27th. Pfizer’s dividend payout ratio is currently 32.28%.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research analyst reports. Daiwa Capital Markets lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target for the company. in a research report on Thursday, May 11th. UBS Group decreased their target price on shares of Pfizer from $41.00 to $39.00 in a research note on Friday, May 5th. Credit Suisse Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $47.00 to $40.00 in a research note on Thursday. Barclays reduced their price objective on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Finally, Jefferies Financial Group assumed coverage on Pfizer in a research report on Monday, March 6th. They issued a “hold” rating and a $43.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $46.67.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.